{"id":"NCT01942148","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia","officialTitle":"A Multicenter, Open-label, Long-term Safety Study of Aripiprazole (Initial Dose 2 mg/Day, Maintenance Dose 6-24 mg/Day, Maximum Dose 30 mg/Day) Orally Administered Over 52 Weeks in Patients Who Complete a Short-term Treatment Study of Aripiprazole in Pediatric Patients (Aged 13-17 Years) With Schizophrenia (031-09-003 Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-08","primaryCompletion":"2015-11","completion":"2015-11","firstPosted":"2013-09-13","resultsPosted":"2017-06-28","lastUpdate":"2017-06-28"},"enrollment":68,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Aripiprazole","otherNames":["Abilify"]}],"arms":[{"label":"Aripiprazole","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to investigate the safety and efficacy of aripiprazole (initial dose 2 mg/day, maintenance dose 6-24 mg/day, maximum dose 30 mg/day) orally administered over a period of 52 weeks in subjects who complete a short-term treatment study of pediatric patients (aged 13-17 years) with schizophrenia (031-09-003 study).","primaryOutcome":{"measure":"Mean Change From Baseline at Final Assessment in Positive and Negative Syndrome Scale (PANSS) Total Score","timeFrame":"Basline and Week52","effectByArm":[{"arm":"Aripiprazole","deltaMin":-7.9,"sd":28.2}],"pValues":[]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":16},"locations":{"siteCount":8,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":68},"commonTop":["Nasopharyngitis","Somnolence","Nausea","Vomiting","Headache"]}}